ORP Surgical, LLC v. Howmedica Osteonics Corp.

CourtDistrict Court, D. Colorado
DecidedMay 10, 2022
Docket1:20-cv-01450
StatusUnknown

This text of ORP Surgical, LLC v. Howmedica Osteonics Corp. (ORP Surgical, LLC v. Howmedica Osteonics Corp.) is published on Counsel Stack Legal Research, covering District Court, D. Colorado primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
ORP Surgical, LLC v. Howmedica Osteonics Corp., (D. Colo. 2022).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLORADO Senior Judge R. Brooke Jackson

Civil Action No. 1:20-cv-01450-RBJ

ORP SURGICAL, LLP, a Colorado limited liability company, and LEE PETRIDES,

Plaintiffs,

v.

HOWMEDICA OSTEONICS CORP, a New Jersey corporation,

Defendant.

FINDINGS OF FACT, CONCLUSIONS OF LAW, AND ORDER OF JUDGMENT

This case was tried to the Court beginning December 13, 2021 to December 17, 2021. After a COVID-imposed hiatus, the case concluded on March 1, 2, and 4, 2022. Plaintiffs ORP Surgical, LLP (ORP) and its primary owner, Lee Petrides, brought suit against Howmedica Osteonics Corp., a subsidiary of Stryker Corp., for alleged wrongful actions done during the winding down of business relations between the two companies. Defendant, which I will refer to as “Stryker,” brought counterclaims against ORP and Mr. Petrides. I. BACKGROUND This section summarizes the parties’ relationship and lays out uncontroversial facts. I resolve the disputed factual questions in later sections. In describing the background and making my findings of fact, the Court has considered the reporter’s certified transcript, the exhibits admitted into evidence, and the Court’s own notes, recollections, and impressions of the evidence. Stryker manufactures medical implants. The products relevant to this case fall into two categories: joint products, which are generally used in elective joint replacement surgeries, and trauma products, which are generally used in emergency surgeries after traumatic accidents. Selling these Stryker products requires a specialized skillset; sales representatives (“reps”) not

only need to develop relationships with the surgeons to whom they sell, but they also need sufficient medical knowledge to advise and guide the surgeons in the use of Stryker products from inside the operating room. Effective sales reps are the lifeblood of this market. Stryker employs some of its own sales reps in and around Colorado through Summit Surgical, a fully owned subsidiary. It also contracted with plaintiff ORP, an independent company with sales reps who sold Stryker products on commission. A substantial portion of Stryker’s joint and trauma sales in the region had, until the events in this case, come through ORP; and the two companies appear to have enjoyed a close working relationship. Two documents comprised the bedrock of this relationship: the Joint Sales Representative Agreement (“joint SRA” or “joint contract”) and the Trauma Sales Representative Agreement (“trauma

SRA” or “trauma contract”).1 Each of these contracts granted ORP the exclusive right to sell Stryker products in certain locations, specified which non-Stryker products ORP could and could not sell, and permitted either party to voluntarily terminate the contract so long as they complied with certain post-termination restrictions. Both contracts provided that, in the event of such a termination, ORP would have to sit on the sidelines for a year — the provisions prohibiting ORP from selling products competitive with Stryker would survive the contract by twelve months. In return, Stryker would have to pay ORP “restriction payments” equal to ORP’s commissions from

1 These contracts were made between Stryker, ORP (designated as “Representative”), and Mr. Petrides (designated as “Principal”). Stryker sales made in the twelve months before termination. Both contracts also contained one- year non-solicitation/non-divert provisions that would survive the contract.2 The two companies’ ties ran deeper than just contracts. Some ORP principals had previously worked for Stryker; Stryker helped train ORP sales reps; and ORP sales reps sold

more products from Stryker than any other manufacturer — and were generously rewarded for their efforts. The companies’ relationship soured. Stryker brought in a new Area Vice President, Adam Jacobs, from its Houston office in October 2018. On March 27, 2019, Mr. Jacobs informed Mr. Petrides that Stryker was terminating the joint contract for “cause.” When Mr. Jacobs terminated the joint contract, Stryker took the position that ORP had materially breached the contract and, as a result, Stryker was not bound by the contract’s terms and was not obligated to pay restriction payments. ORP took the position that Stryker did not have “cause” to terminate the joint contract, and that the voluntary termination payment obligations, sales restrictions, and non-solicit/non-divert covenants should have applied.

At the same time as it terminated the joint contract, Stryker offered ORP a deal: Stryker would still pay the restriction payments if ORP would waive the non-solicit/non-divert provision and allow Stryker to hire ORP sales rep James Demorest. ORP declined. A few months later, Stryker hired Mr. Demorest anyway. The trauma contract remained in place, but Stryker informed ORP in October 2018 that it wanted to negotiate a mutually agreeable termination. Mr. Jacobs sent Mr. Petrides two offers.

2 The restriction payments were owed to “Representative,” i.e., ORP. Trauma Contract (Pl. ex. 5) § 16.3. The non-solicit/non-divert provision was made explicitly “for the reasonable protection of the Representative,” and with the understanding that “any breach of the [non-solicit/non-divert provision] will result in irreparable harm and continuing damage to the Representative.” Id. at § 16.2. Neither provision mentioned Mr. Petrides. The first would have made ORP a Stryker agent. ORP declined. The second was essentially a buyout; it offered $8 million to terminate the trauma contract, waive the restriction payments, and permit Stryker to solicit and hire ORP’s sales force. Mr. Petrides met with Mr. Jacobs at a Starbucks and counteroffered: $13.6 million and a few other terms memorialized in shorthand on

a sticky note. Plaintiffs claim that Mr. Jacobs accepted the offer on the spot. Stryker maintains that Mr. Jacobs agreed in principle to the bottom-line number but did not make a deal. In any case, Mr. Jacobs sent Mr. Petrides a proposal on March 31, 2020. This proposal partially tied the buyout price to Stryker hiring ORP sales reps. ORP would receive $8 million for terminating the contract and waiving the non-solicitation/non-divert, and it would receive additional money for each sales rep hired by Stryker. If Stryker hired all 14 ORP reps it wanted, ORP would receive the $13.6 million Mr. Petrides had requested. This proposal deepened the fractures in the ORP-Stryker relationship. According to Mr. Petrides, Mr. Jacobs paired the proposal with a threat: sign it by Friday April 3 or Mr. Jacobs would terminate the trauma contract for “cause” and refuse to provide ORP the restriction

payments. Mr. Petrides claimed to find the threat credible because, in his view, Mr. Jacobs had baselessly terminated the joint contract for “cause” just a few months earlier. Mr. Jacobs denies having issued any such threat. What happened next, however, is undisputed — Mr. Petrides decided to voluntarily terminate the trauma contract himself. On April 3, 2020 Mr. Petrides provided Mr. Jacobs the requisite 30-day notice of termination. This notice did not release the parties from their contractual obligations, including the one-year non-solicit/non-divert. The trauma contract therefore ended at 11:59:59 p.m. on May 3, 2020. Stryker offered to hire at least 11 ORP reps within the first two hours after the contract ended. Within 48 hours, 12 ORP reps had been hired by Stryker. ORP alleges that Stryker impermissibly solicited and/or diverted these reps. Stryker denies the allegations. ORP sued on May 21, 2020. ORP ultimately tried two claims before the Court: (1) corporate raiding; and (2) breach of contract, which included alleged breaches of both the joint and trauma contracts.3 Stryker brought four counterclaims: (1) breach of the joint contract; (2)

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Seaward Const. Co., Inc. v. Bradley
817 P.2d 971 (Supreme Court of Colorado, 1991)
Nappe v. Anschelewitz, Barr, Ansell & Bonello
477 A.2d 1224 (Supreme Court of New Jersey, 1984)
Caldwell v. Haynes
643 A.2d 564 (Supreme Court of New Jersey, 1994)
Hamon Contractors, Inc. v. Carter & Burgess, Inc.
229 P.3d 282 (Colorado Court of Appeals, 2009)
Town of Alma v. AZCO Construction, Inc.
10 P.3d 1256 (Supreme Court of Colorado, 2000)
Great Am. Opportunities, Inc. v. Kent
352 F. Supp. 3d 1126 (D. Colorado, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
ORP Surgical, LLC v. Howmedica Osteonics Corp., Counsel Stack Legal Research, https://law.counselstack.com/opinion/orp-surgical-llc-v-howmedica-osteonics-corp-cod-2022.